ArticleGenes and immunity2026
Hspa8 modulation of immune responses mitigates ischemic brain injury.
Article in Genes and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ischemic brain injury triggers complex immune-inflammatory responses that significantly influence disease progression and patient outcomes. This study investigates the role of heat shock protein A8 (Hspa8) in modulating immune cell dynamics following ischemic brain injury. Using single-cell RNA sequencing, bulk RNA sequencing, flow cytometry, and immunofluorescence, we identified significant alterations in T cells, neutrophils, and monocytes within both peripheral blood and brain tissues. Our findings reveal that Hspa8 plays a pivotal role in regulating neutrophil infiltration and reactive oxygen species (ROS) production. Gene silencing of Hspa8 effectively reduced neutrophil accumulation, decreased ROS levels, and mitigated neurological deficits in both in vitro and in vivo ischemic models. Protein-protein interaction (PPI) network analysis further established Hspa8 as a key regulator in immune cell interactions, highlighting its potential as a therapeutic target. These results provide new insights into the immune mechanisms underlying ischemic brain injury and suggest that targeting Hspa8 may offer a promising strategy for reducing inflammation, improving neurological recovery, and enhancing clinical outcomes in affected patients.
Indexed as
Identifiers
41176589What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.